EP2758421A4 - Zusammensetzungen und verfahren in zusammenhang mit gewebetargeting - Google Patents
Zusammensetzungen und verfahren in zusammenhang mit gewebetargetingInfo
- Publication number
- EP2758421A4 EP2758421A4 EP12833225.1A EP12833225A EP2758421A4 EP 2758421 A4 EP2758421 A4 EP 2758421A4 EP 12833225 A EP12833225 A EP 12833225A EP 2758421 A4 EP2758421 A4 EP 2758421A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods related
- tissue targeting
- targeting
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161538322P | 2011-09-23 | 2011-09-23 | |
PCT/US2012/056333 WO2013043870A1 (en) | 2011-09-23 | 2012-09-20 | Compositions and methods related to tissue targeting |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2758421A1 EP2758421A1 (de) | 2014-07-30 |
EP2758421A4 true EP2758421A4 (de) | 2015-03-25 |
Family
ID=47914860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12833225.1A Withdrawn EP2758421A4 (de) | 2011-09-23 | 2012-09-20 | Zusammensetzungen und verfahren in zusammenhang mit gewebetargeting |
Country Status (3)
Country | Link |
---|---|
US (1) | US20140356285A1 (de) |
EP (1) | EP2758421A4 (de) |
WO (1) | WO2013043870A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200113829A1 (en) * | 2018-10-12 | 2020-04-16 | Synergene Therapeutics, Inc. | Methods for reducing side effects of immunotherapy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005065418A2 (en) * | 2003-12-31 | 2005-07-21 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy |
US20070122414A1 (en) * | 2005-11-10 | 2007-05-31 | Aurelium Biopharma Inc. | Surface marker-directed cancer therapeutics |
WO2007061922A2 (en) * | 2005-11-17 | 2007-05-31 | Children's Medical Center Corporation | Methods to predict and prevent resistance to taxoid compounds |
US20100172864A1 (en) * | 2001-09-07 | 2010-07-08 | Wadih Arap | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5663299A (en) * | 1989-02-23 | 1997-09-02 | Center For Blood Research, Inc. | Human monocyte elastase inhibitor |
EP1231936A2 (de) * | 1999-10-27 | 2002-08-21 | K-Quay Enterprises, LLC | Verfahren und zusammensetzungen für behandlung von keratokonus mit proteaseinhibitoren |
AU4347701A (en) * | 2000-03-01 | 2001-09-12 | Corixa Corp | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US6806082B2 (en) * | 2000-12-22 | 2004-10-19 | Microbia, Inc. | Isolated nucleic acid molecule encoding a regulator of fungal gene expression |
EP1649289B1 (de) * | 2003-07-21 | 2008-10-22 | Roche Diagnostics GmbH | Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome |
US7468350B2 (en) * | 2004-06-16 | 2008-12-23 | Pneumrx, Inc. | Glue composition for lung volume reduction |
US8168748B2 (en) * | 2005-08-04 | 2012-05-01 | North Carolina State University | Peptide aptamers that bind to the rep proteins of ssDNA viruses |
-
2012
- 2012-09-20 WO PCT/US2012/056333 patent/WO2013043870A1/en active Application Filing
- 2012-09-20 US US14/346,421 patent/US20140356285A1/en not_active Abandoned
- 2012-09-20 EP EP12833225.1A patent/EP2758421A4/de not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100172864A1 (en) * | 2001-09-07 | 2010-07-08 | Wadih Arap | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
WO2005065418A2 (en) * | 2003-12-31 | 2005-07-21 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy |
US20070122414A1 (en) * | 2005-11-10 | 2007-05-31 | Aurelium Biopharma Inc. | Surface marker-directed cancer therapeutics |
WO2007061922A2 (en) * | 2005-11-17 | 2007-05-31 | Children's Medical Center Corporation | Methods to predict and prevent resistance to taxoid compounds |
Non-Patent Citations (2)
Title |
---|
KOLONIN M G ET AL: "Reversal of obesity by targeted ablation of adipose tissue", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 10, no. 6, 1 June 2004 (2004-06-01), pages 625 - 632, XP002363820, ISSN: 1078-8956, DOI: 10.1038/NM1048 * |
See also references of WO2013043870A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP2758421A1 (de) | 2014-07-30 |
WO2013043870A1 (en) | 2013-03-28 |
US20140356285A1 (en) | 2014-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285985A (en) | Therapeutic nuclease preparations and methods | |
HK1256896A1 (zh) | 用於實現多重cold-pcr的方法和組合物 | |
EP2717926A4 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von biofilmen | |
EP2675471A4 (de) | Mit hsa zusammenhängende zusammensetzungen und verwendungsverfahren | |
SG10201602752XA (en) | Melanin modification compositions and methods of use | |
GB201002249D0 (en) | Improvements in or relating to methods of manufacture | |
EP2648706A4 (de) | Zusammensetzungen und verfahren im zusammenhang mit proliferativen erkrankungen | |
EP2680837A4 (de) | Zusammensetzungen und verfahren mit c16:1n7-palmitoleat | |
ZA201209705B (en) | Ipmrovements in or relating to ophthalmology | |
ZA201209701B (en) | Improvements in or relating to ophthalmology | |
IL250307A0 (en) | Pesticide preparations and methods | |
EP2753337A4 (de) | Zusammensetzungen mit beta-glucanen und verwendungsverfahren | |
EP2755668A4 (de) | Zusammensetzungen aus hyr1 und behandlungsverfahren damit | |
ZA201308892B (en) | Compositions and methods | |
EP2668044A4 (de) | Zusammensetzungen und ihre verwendung | |
EP2558506A4 (de) | Gewebeanzielung | |
GB201011094D0 (en) | Improvements in or relating to ophthalmology | |
ZA201305342B (en) | Improvements in and relating to compositions | |
EP2766357A4 (de) | Mesobiliverdinzusammensetzungen und verfahren dafür | |
EP2742139A4 (de) | Immunogene zusammensetzungen und verfahren dafür | |
IL231490A0 (en) | Preparations and methods for the production and use of human cholinesterases | |
EP2758421A4 (de) | Zusammensetzungen und verfahren in zusammenhang mit gewebetargeting | |
PL2736328T3 (pl) | Biocydowe kompozycje oraz sposoby stosowania | |
PL2736339T3 (pl) | Biocydowe kompozycje oraz sposoby stosowania | |
GB201003741D0 (en) | Methods and therapeutic compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140328 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150225 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/00 20060101AFI20150219BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150924 |